Illinois pharmaceutical company Abbott Laboratories notified 700 employees Wednesday that they will be out of work.

The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.

The latest revision of the Diagnostic and Statistical Manual of Mental Disorders may put an end to classifying bereavement as something other than depression, though it's not clear that will mean much of a bump in the market for antidepressants.

Seven weeks after Pfizer's main Lipitor patent expired in the US, the drug is down to 32% market share and at least one name-brand analyst is casting doubt on the brand's survival strategy.

Sen. Chuck Grassley (R-IA) put 34 Medicaid programs on notice that they are not doing enough to rein in over prescription of certain drugs and he wants to know why.

Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.

Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug's label that could boost sales by helping doctors avoid a serious adverse event.

Damon Marquis wants to make one thing clear: CME is not the only important form of medical education.

Those who produce and fund certified medical education acknowledge that conflict of interest is one issue that seems to constantly crop up. But while conflict is inevitable, bias doesn't have to be, they insist in a new video.

Takeda said it will slash its global workforce by around 2,800 jobs - 700 of those in the US and the rest in Europe - as it absorbs Nycomed and moves toward a more diverse product portfolio.

FDA's first draft guidance to come out of its 2009 online communication hearing offers sound counsel but not much in the way of specifics, writes Peter Pitts. The takeaway: where the letter of the law is hazy, exercise your judgement and follow, as best you can, the spirit of the law.

FDA's recent draft guidance on off-label communication is, despite its shortcomings, a step forward, writes John Kamp, arguing that pharmas should take this welcome bit of clarity and act boldly on it